These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26262830)

  • 1. Options in metastatic urothelial cancer after first-line therapy.
    Alimohamed NS; Sridhar SS
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):255-60. PubMed ID: 26262830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Treatment of Metastatic Urothelial Carcinoma.
    Bukhari N; Al-Shamsi HO; Azam F
    ScientificWorldJournal; 2018; 2018():5682078. PubMed ID: 29977169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of metastatic disease: cisplatin-ineligible patients.
    Cathomas R; De Santis M; Galsky MD
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment of metastatic bladder cancer and future directions.
    Lei AQ; Cheng L; Pan CX
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab in urothelial bladder carcinoma.
    Hamilou Z; Lavaud P; Loriot Y
    Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
    Abida W; Bajorin DF; Rosenberg JE
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):319-28, ix-x. PubMed ID: 25836937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects and progress of immunotherapy for bladder cancer.
    Boegemann M; Aydin AM; Bagrodia A; Krabbe LM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1417-1431. PubMed ID: 28832261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of bladder cancer: current and emerging strategies.
    Agarwal N; Hussain M
    Drugs; 2009 Jun; 69(9):1173-87. PubMed ID: 19537835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future directions and targeted therapies in bladder cancer.
    Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy for urothelial cancer of the bladder--update 2012].
    Niegisch G; Lorch A; Albers P
    Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic bladder cancer: anything new?
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):304-9. PubMed ID: 22643704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.